图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
肿瘤形成评论综述™
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN 打印: 0893-9675
ISSN 在线: 2162-6448

肿瘤形成评论综述™

DOI: 10.1615/CritRevOncog.v16.i1-2.30
pages 13-24

Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia

Sarah Tasian
The Children's Hospital of Philadelphia
Mignon L. Loh
Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of California San Francisco, San Francisco, California

ABSTRACT

Recent genomic analyses of childhood and adult B-precursor acute lymphoblastic leukemia (ALL) samples have identified novel genetic alterations in essential lymphoid development and signal transduction pathways, providing insight into the pathogenesis of high-risk ALL associated with treatment failure. Particular advances have been made in unraveling the genetics of ALL associated with overexpression of the cytokine receptor-like factor 2 gene (CRLF2), which is frequently accompanied by simultaneous activating mutations in genes encoding Ikaros (IKZF1), Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), and/or the IL-7 receptor alpha chain (IL7RA). Children and adults with high-risk CRLF2-overexpressing ALL have high rates of relapse and dismal overall survival. Various groups have thus attempted to characterize the biochemical consequences of these genetic lesions via preclinical models with the goal of identifying targets for new therapies. These studies provide early data suggesting the promise of signal transduction inhibitors (STIs) of the JAK/STAT and PI3K pathways for CRLF2-overexpressing ALL. Additional research efforts continue to elucidate these aberrant signaling networks to provide rationale for bringing STIs into the clinic for these high-risk patients. This review highlights the current knowledge of the incidence, prognostic significance, and biology of CRLF2-overexpressing ALL and future directions for development of targeted therapies.


Articles with similar content:

Pediatric Brain Tumors: Genomics and Epigenomics Pave the Way
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 3-4
Adam M. Fontebasso , Nada Jabado
The Importance of Mutational Drivers in GBM
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 1
Rasime Kalkan
Ikaros and Tumor Suppression in Acute Lymphoblastic Leukemia
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 1-2
Sinisa Dovat, Kimberly J. Payne
Hypoxia Is the Driving Force Behind GBM and Could Be a New Tool in GBM Treatment
Critical Reviews™ in Eukaryotic Gene Expression, Vol.25, 2015, issue 4
Rasime Kalkan
The Oncogenic Role of Human Papillomavirus Proteins
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 1-2
Miguel S. Barbosa